Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery
Conditions: DMMR Colorectal Cancer; Anti PD-1; Immunotherapy Interventions: Drug: Tisleizumab(BGB-A317) Sponsors: Sun Yat-sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Immunotherapy | Neoadjuvant Therapy | Research